A Study to Assess LY4100511 (DC-853) in Healthy Adult Participants
Status:
COMPLETED
Trial end date:
2024-06-18
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess the effect of multiple doses of itraconazole, fluconazole, and carbamazepine on single dose pharmacokinetic of LY4100511 (DICE-853) in healthy participants. The study will also evaluate the safety and tolerability of LY4100511 (DICE-853) with itraconazole, fluconazole, and carbamazepine.
Phase:
PHASE1
Details
Lead Sponsor:
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company